Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05281471IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumab; at most 24 months since last dose of prior platinum therapy - intraperitoneal infusionA Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)AL, AZ, CA, FL, IN, MD, MI, MO, NV, NC, OH, OK, PA, SC, TN, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Olvimulogene nanivacirepveclight-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1Induces immune response and tumor cell lysisClinical Trials
NCT03767348I/IIAdvanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT04282044IAdvanced solid tumorsA Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid MalignanciesAZ, CAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CRX100autologous cytokine-induced killer cells/vaccinia virus DD-CDSR CRX100, CRX-100Induces immune response and tumor cell lysisClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04053283IAdvanced solid tumors (inc expansion)A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)CA, FLView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NG-641enadenotucirev-expressing FAP/CD3 bispecific FAP-TAc NG-641Induces immune response and tumor cell lysisClinical Trials
NCT05043714IAdvanced solid tumors (inc expansion)A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-641, a Tumour-selective and Transgene-expressing Adenoviral Vector, in Combination With Nivolumab (or Standard of Care PD-1 Inhibition) in Patients With Metastatic or Advanced Epithelial Tumours (NEBULA)CA, FL, OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NG-641enadenotucirev-expressing FAP/CD3 bispecific FAP-TAc NG-641Induces immune response and tumor cell lysisClinical Trials
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05057715IPersistent or recurrent serous ovarian cancerPhase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
huCART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
VCN-01PH20 hyaluronidase-expressing adenovirus VCN-01Induces immune response and tumor cell lysisClinical Trials
NCT05165433IAdvanced solid tumors (inc expansion)A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial TumoursCA, FL, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NG-350Aenadenotucirev-expressing anti-CD40 agonistic monoclonal antibody NG-350, oncolytic adenoviral vector-expressing anti-CD40 agonistic antibodyInduces immune response and tumor cell lysisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05271318IRecurrent ovarian cancerA Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer.MN, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Igrelimogene litadenorepvecTNFalpha/IL-2-encoding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT-123Induces immune response and tumor cell lysisClinical Trials
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05346484IAdvanced solid tumors - optional intratumoral injection (in expansion)A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).AZ, AR, CA, FL, MI, OH, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CF33-hNISCF33-hNIS (hNIS - human sodium iodide symporter), VAXINIA, HOV2Induces immune response and tumor cell lysisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05901285IAdvanced solid tumors (inc expansion) - intratumoral injectionPhase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced SolidAZ, CO, DC, MAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VAX014recombinant bacterial minicells VAX014Induces immune response and tumor cell lysisClinical Trials
NCT05938296IAdvanced solid tumors - intratumoral injectionA Phase 1, Open-label Study of BS006, an Oncolytic Virus, Administered by Intratumoral Injection in Patients With Advanced/Metastatic Solid TumorsFLView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BS006oncolytic type 2 herpes simplex virus expressing anti-PD-L1/CD3 bispecific antibody BS-006Induces immune response and tumor cell lysisClinical Trials
NCT06063317IAdvanced solid tumors (inc expansion)A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)CA, OH, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BlinatumomabRe-directs T cells to attack CD19+ tumor cellsApproved in Other Cancers
CF33-CD19Induces immune response and tumor cell lysis and expression of CD19 on tumor cellsClinical Trials
NCT06171178IAdvanced solid tumors (inc ovarian expansion)A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants With Locally Advanced or Metastatic Solid TumorsCA, IA, MI, NC, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ASP1012VET2-L2Induces immune response and tumor cell lysisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.